Novo Nordisk A/S stock is trading -89.16% below its average target price of $941.31 after marking a 2.2% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $584.235 to $1144.722 per share.
Novo Nordisk A/S's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.2%. The stock's short ratio is 1.26. At 0.0%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.
Another number to watch is the company's rate of institutional share ownership, which now stands at 10.2%. In conclusion, we believe there is mixed market sentiment regarding Novo Nordisk A/S.
Institutions Invested in Novo Nordisk A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Jennison Associates LLC | 1% | 20,195,957 | $2,060,694,546 |
| 2024-09-30 | FMR, LLC | 1% | 17,931,577 | $1,829,648,524 |
| 2024-09-30 | Morgan Stanley | 0% | 14,365,402 | $1,465,773,845 |
| 2024-09-30 | Bank of America Corporation | 0% | 14,326,429 | $1,461,797,235 |
| 2024-09-30 | Fisher Asset Management, LLC | 0% | 13,305,474 | $1,357,624,088 |
| 2024-09-30 | Sarofim, Fayez & Co | 0% | 12,217,118 | $1,246,573,679 |
| 2024-09-30 | Price (T.Rowe) Associates Inc | 0% | 9,583,435 | $977,845,825 |
| 2024-09-30 | Folketrygdfondet | 0% | 8,863,625 | $904,400,009 |
| 2024-09-30 | Loomis Sayles & Company, LP | 0% | 8,623,915 | $879,941,198 |
| 2024-09-30 | Renaissance Technologies, LLC | 0% | 8,189,315 | $835,596,786 |
